Skip to Content
Merck

Key Documents

View All Documentation

Z-005

Zonisamide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C8H8N2O3S
CAS Number:
68291-97-4
Molecular Weight:
212.23
NACRES:
NA.24
PubChem Substance ID:
329831593
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
MFCD00865316
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

NS(CC1=NOC2=C1C=CC=C2)(=O)=O

InChI

1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)

InChI key

UBQNRHZMVUUOMG-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

General description

Zonisamide is a second-generation anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, and generalized tonic-clonic seizure. Zonisamide is marketed in the US under the trade name Zonegran®.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zonegran is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.

Disclaimer

Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Y Chung et al.
New Zealand veterinary journal, 60(6), 357-359 (2012-05-30)
To evaluate the efficacy of zonisamide as a monotherapy in dogs with idiopathic epileptic seizure. The experiment was conducted on 10 dogs with idiopathic epilepsy that were treated at the Seoul National University Hospital for Animals. A diagnosis was conducted
Vedat Ali Yürekli et al.
Cellular and molecular neurobiology, 33(2), 205-212 (2012-12-12)
Parkinson's disease is an incurable progressive neurological condition caused by a degeneration of dopamine-producing cells characterized by motor and non-motor symptoms. The major mechanisms of the antiepileptic actions of ZNS are inhibition of voltage-gated Na(+) channel, T-type voltage-sensitive Ca(2+) channel
Zonisamide for the treatment of self-inflicted dermatoses related to impulse control disorders.
Maria José Tribó et al.
Archives of dermatology, 148(6), 762-764 (2012-06-20)
View All Related Papers